Fennec Pharmaceuticals (FENC) CMO Pierre Sargis Receives 168 Restricted Shares

What Happened Pierre Sargis, Chief Medical Officer of Fennec Pharmaceuticals, reported an acquisition on Sep 30, 2026: 168 shares were released from restriction and reported as an award/acquisition (code A) at $0.00 per share (total reported value $0). This was not a market purchase or sale but the vesting/release of previously awarded restricted shares.

Key Details

• Transaction date: 2026-09-30; Form 4 filed: 2026-10-01 (timely filing).
• Transaction type/code: Award/Grant release (A).
• Shares involved: 168 shares acquired at $0.00 each; total reported value $0.
• Footnote: These 168 shares were released from restriction from an award granted 2025-03-28 (footnote F1).
• Shares owned after the transaction: Not specified in the filing summary provided.
• No 10b5-1 plan, tax-withholding, cashless exercise, or sale was indicated.

Context This transaction represents the vesting/release of previously awarded restricted stock rather than a new cash purchase or a sale. Such releases are common as part of compensation and do not, by themselves, indicate a buy or sell signal; they simply convert restricted awards into freely held shares for the insider.